Free shipping on all orders over $ 500


Cat. No. M1661
AZD6244 Structure

Selumetinib, ARRY-142886

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL USD 60  USD60 In stock
25mg USD 35  USD35 In stock
50mg USD 60  USD60 In stock
100mg USD 90  USD90 In stock
200mg USD 130  USD130 In stock
500mg USD 240  USD240 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

AZD6244 (ARRY-142886, Selumetinib) is a potent MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nM. AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.

Product Citations
Customer Product Validations & Biological Datas
Source Apoptosis (2018). Figure 6. AZD6244 (Abmole Bioscience. USA)
Method Western Blot
Cell Lines HT29 and SW480 cells
Concentrations 32 μmol/l
Incubation Time 24 h
Results Resembling the WB results from the BZA treatment, the inhibitors AG490, NVP-BEZ23 and AZD6244 imitated BZA function, down-regulating the pivotal protein of the JAK/STAT3, PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signal pathways
Source Apoptosis (2018). Figure 5. AZD6244 (Abmole Bioscience. USA)
Method cell apoptosis assay
Cell Lines HT29 and SW480 cells
Concentrations 32 μmol/l
Incubation Time 24 h
Results In addition, using the respective AG490 (50 μmol/l), NVP-BEZ235 (96 nmol/l) and AZD6244 (32 μmol/l) inhibitors for 24 h to mimic the BZA effect in colon cancer cells, we observed that the Bad/Bcl-2 ratio was significantly up-regulated and that Ki-67 mRNA expression was substantially down-regulated in this treatment group compared with the control group
Source Cell Biol Int (2014). Figure 5. AZD6244
Method Western blots
Cell Lines Raji and MOLT-4 cells
Concentrations 10 μM
Incubation Time 48 h
Results Consistent with role in the growth inhibition, silencing of Bim decreases the AZD6244-induced apoptosis (Figure 5D) and abrogates AZD6244 induced G1 arrest (Figure 5E).
Source Cell Biol Int (2014). Figure 1. AZD6244
Method apoptosis assay
Cell Lines Raji and MOLT4 cells
Concentrations 10 μM
Incubation Time 48 h
Results AZD6244 significantly blocked ERK phosphorylation in Raji and MOLT4 cells (Figure 1A). AZD6244 significantly inhibited proliferation of both Raji and MOLT4 in a dose-dependent manner (n¼3, P<0.01; Figure 1B).
Protocol (for reference only)
Cell Experiment
Cell lines HT-29, Malme-3M, MIAPaCa-2, SK-MEL-2, SK-MEL-28, BxPC3, BT-474, Zr-75-1, Malme-3
Preparation method Cellular viability assays Cells plated in 96-well plates were incubated with multiple concentrations of compound for 3 days. The number of viable cells was determined using the CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay (Promega, Madison, WI).
Concentrations 0-50µM
Incubation time 3 days
Animal Experiment
Animal models HT-29 and BxPC3 xenograft
Formulation 10% ethanol/10% cremophor EL/80% D5W
Dosages 10, 25, 50, or 100 mg/kg BID
Administration oral
Chemical Information
Molecular Weight 457.68
Formula C17H15BrClFN4O3
CAS Number 606143-52-6
Solubility (25°C) DMSO 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Yuen et al. Int J Oncol. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.

[2] Ma BB et al. Invest New Drugs. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.

[3] Patel et al. Expert Opin Investig Drugs. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

[4] Holt et al. Br J Cancer. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

[5] Bartholomeusz et al. Mol Cancer Ther. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Related MEK Products

MAP855 is a potent, selective and orally effective ATP-competitive MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 inhibits wild-type and mutant MEK1/2 equally.


WAY-114228 is a MEK1 inhibitor.

Trametinib (DMSO solvate)

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM.

Selumetinib sulfate

Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

MEK inhibitor

MEK inhibitor is a potent MEK inhibitor with antitumor potency.

Abmole Inhibitor Catalog

Keywords: AZD6244, Selumetinib, ARRY-142886 supplier, MEK, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.